Evidence for enhanced oxidative stress in coronary heart disease and chronic heart failure

Advances in Experimental Medicine and Biology

Volumn 525, Issue , 2003, Pages 197-200

  Wolfram, Roswitha ^a   Oguogho, Anthony ^a   Palumbo, Barbara ^b   Sinzinger, Helmut ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PERUGIA   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; EDETIC ACID; ISOPROSTANE;

ANTICOAGULATION; BLOOD SAMPLING; CARDIOVASCULAR RISK; CENTRIFUGATION; CIGARETTE SMOKING; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VALVE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN URINE LEVEL;

EID: 0037530206     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-9194-2_42     Document Type: Conference Paper

References (7)

1. 2-isoprostanes in patients with severe heart failure. Heart 2000; 84: 439-440.
2. McMurray J, Chopra M, Abdullah I. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14: 1493-1498.
3. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997; 36: 1-21.
4. 2α. Brit J Pharmacol 1996; 119: 1276-1280.
5. 2α, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc Res 1999; 43: 492-499.
6. 2α a valuable indicator of oxidative injury in human heart valves. Cardiovasc Pathol 2001; 10: 241-245.
7. 2α. J Am Coll Cardiol 2003 (submitted).